From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.
Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.
When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).
Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk.
Pharmac has identified five key drivers of medicine access equity in New Zealand. Read on to learn about the drivers and how you can implement them in your place of work.
Cultural competence vs safety – related, but different
A culturally competent practitioner knows about the beliefs and behaviours of patients from different cultures, and has the skill to apply this knowledge to healthcare delivery.
Read the HAH Bulletin to find out more.
Careful writing and editing, and an equity lens, have been instrumental in updating the type 2 diabetes HealthPathways, helping to reduce unnecessary variation in treatment plans and outcomes.
Compliance, adherence, concordance – confused?
Whatever terminology is used, studies show that differences in health literacy, medicines access, attitudes to health and prescriber perceptions, may contribute to sub-optimal use of medicines and poor health outcomes.1
Read the HAH Bulletin to find out about strategies to improve medicine access/supply.
Focusing on the experiences of older Māori in primary care, this course comprises four short videos, an independent reflection, downloadable posters and additional resources.
The course is endorsed by RNZCGP and CNA(NZ) and meets PCNZ recertification requirements. Reflection templates are included for you to complete.
This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.
Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.
This is a Measuring and Improving Outcomes (MIO) activity that meets RNZCGP CPD requirements.
Māori attitudes to healthcare today are deeply rooted in New Zealand history. In this article, Deborah Bassett-Clarke discusses some reasons why the current model of pharmacy practice does not always meet the needs of Māori and may actually cause health inequities. Understanding these factors is an important first step to improving outcomes for Māori.
Medicine affordability is one of the five drivers of medicine access equity.
Up to 40 per cent of people continue to pay prescription copayments even though they are entitled to an exemption.1 No person or family should pay more than $100 per annum for subsidised medicines.
Read the HAH bulletin to find out more.